CA3263977A1 - INTRANASAL ADMINISTRATION OF BDNF FOR THE TREATMENT OF NEUROSENSORIAL HEARING LOSS - Google Patents

INTRANASAL ADMINISTRATION OF BDNF FOR THE TREATMENT OF NEUROSENSORIAL HEARING LOSS

Info

Publication number
CA3263977A1
CA3263977A1 CA3263977A CA3263977A CA3263977A1 CA 3263977 A1 CA3263977 A1 CA 3263977A1 CA 3263977 A CA3263977 A CA 3263977A CA 3263977 A CA3263977 A CA 3263977A CA 3263977 A1 CA3263977 A1 CA 3263977A1
Authority
CA
Canada
Prior art keywords
bdnf
treatment
hearing loss
intranasal administration
sensorineural hearing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3263977A
Other languages
English (en)
French (fr)
Inventor
Anna Rita FETONI
Andrea Aramini
Laura Brandolini
Pasquale COCCHIARO
Tiziana ROMEO
Nicola DETTA
Lucia APPARENTE
Simone MATTIOLI
Franca CATTANI
Flavio Mantelli
Marcello Allegretti
Original Assignee
Dompe Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farmaceutici SpA filed Critical Dompe Farmaceutici SpA
Publication of CA3263977A1 publication Critical patent/CA3263977A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA3263977A 2022-08-05 2023-08-04 INTRANASAL ADMINISTRATION OF BDNF FOR THE TREATMENT OF NEUROSENSORIAL HEARING LOSS Pending CA3263977A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22189067.6 2022-08-05
EP22189067.6A EP4316462A1 (en) 2022-08-05 2022-08-05 Intranasal administration of bdnf for the treatment of sensorineural hearing loss
PCT/EP2023/071676 WO2024028483A1 (en) 2022-08-05 2023-08-04 Intranasal administration of bdnf for the treatment of sensorineural hearing loss

Publications (1)

Publication Number Publication Date
CA3263977A1 true CA3263977A1 (en) 2024-02-08

Family

ID=83080998

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3263977A Pending CA3263977A1 (en) 2022-08-05 2023-08-04 INTRANASAL ADMINISTRATION OF BDNF FOR THE TREATMENT OF NEUROSENSORIAL HEARING LOSS

Country Status (8)

Country Link
US (1) US20260048006A1 (https=)
EP (2) EP4316462A1 (https=)
JP (1) JP2025525990A (https=)
CN (1) CN119816318A (https=)
AU (1) AU2023317860A1 (https=)
CA (1) CA3263977A1 (https=)
IL (1) IL318653A (https=)
WO (1) WO2024028483A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4623926A1 (en) * 2024-03-26 2025-10-01 Dompe' Farmaceutici SpA Intranasal administration of bdnf for treatment of primary headaches

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2278999B1 (en) * 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Auris formulations for treating otic diseases and conditions
WO2019140012A1 (en) * 2018-01-09 2019-07-18 Otonomy, Inc. Growth factor otic formulations
WO2021030452A1 (en) * 2019-08-14 2021-02-18 Decibel Therapeutics, Inc. Permeation enhancers, compositions containing them, and methods of using the same
WO2021151013A1 (en) * 2020-01-24 2021-07-29 Otonomy, Inc. Growth factor formulation for condition associated with otic event
US20240066099A1 (en) * 2020-12-15 2024-02-29 Dompé Farmaceutici S.P.A. Bdnf otic formulations and use thereof

Also Published As

Publication number Publication date
WO2024028483A1 (en) 2024-02-08
EP4565254A1 (en) 2025-06-11
US20260048006A1 (en) 2026-02-19
AU2023317860A1 (en) 2025-02-13
EP4316462A1 (en) 2024-02-07
CN119816318A (zh) 2025-04-11
JP2025525990A (ja) 2025-08-07
IL318653A (en) 2025-03-01

Similar Documents

Publication Publication Date Title
CA3263975A1 (en) INTRANASAL ADMINISTRATION OF NGF FOR THE TREATMENT OF NEUROSENSORY HEARING LOSS
CA3266672A1 (en) POLYTHERAPY
CA3263977A1 (en) INTRANASAL ADMINISTRATION OF BDNF FOR THE TREATMENT OF NEUROSENSORIAL HEARING LOSS
HK40122674A (en) Intranasal administration of ngf for the treatment of sensorineural hearing loss
CA3261397A1 (en) POLYTHERAPY
EP4362963A4 (en) YEAST FOR THE TREATMENT OF INFLAMMATION
HK40117061A (en) Azasetron for the treatment of sudden sensorineural hearing loss
AU2023902197A0 (en) Treatment for tinnitus
CA3269758A1 (en) Bdnf gene therapy
AU2024288814A1 (en) Intra cochlear administration device
CA3296371A1 (en) Intra cochlear administration device
AU2024362751A1 (en) Gene therapy for hearing loss and vestibular disorders
AU2024370739A1 (en) Treatment
CA3289976A1 (en) Rollator
HK40115121A (en) Mirdametinib treatment
AU2023900722A0 (en) Neurogenic Audiological Tinnitus Treatment
HK40128655A (zh) 用於治疗抑郁症的方法
CA3266806A1 (en) METHODS FOR TREATING DEPRESSION
CA3291458A1 (en) Therapy
CA3271207A1 (en) Therapy
CA3278874A1 (en) Tobacco treatment
EM87575790002S (en) Wheelchairs (part of -)
AU2022901826A0 (en) An Improved Wheelchair
AU2022901482A0 (en) Combination treatment
EM91452200001S (lv) Austiņas (- daļa)

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20250128

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250408

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20250408

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250508

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250508

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250508

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250508

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250508